Voya Investment Management LLC Acquires 57,205 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Voya Investment Management LLC lifted its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 342.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 73,914 shares of the company’s stock after purchasing an additional 57,205 shares during the period. Voya Investment Management LLC’s holdings in EyePoint Pharmaceuticals were worth $551,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in EYPT. Adage Capital Partners GP L.L.C. increased its holdings in EyePoint Pharmaceuticals by 51.7% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,750,000 shares of the company’s stock worth $42,838,000 after buying an additional 1,958,580 shares during the last quarter. Federated Hermes Inc. increased its stake in shares of EyePoint Pharmaceuticals by 92.7% during the 4th quarter. Federated Hermes Inc. now owns 3,707,445 shares of the company’s stock worth $27,620,000 after purchasing an additional 1,783,765 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of EyePoint Pharmaceuticals by 24.8% in the 4th quarter. Vanguard Group Inc. now owns 3,803,227 shares of the company’s stock worth $28,334,000 after purchasing an additional 755,045 shares during the period. Blue Owl Capital Holdings LP purchased a new position in EyePoint Pharmaceuticals in the fourth quarter valued at approximately $4,974,000. Finally, Finepoint Capital LP lifted its stake in EyePoint Pharmaceuticals by 57.1% in the fourth quarter. Finepoint Capital LP now owns 1,111,104 shares of the company’s stock valued at $8,278,000 after purchasing an additional 403,700 shares during the last quarter. 99.41% of the stock is owned by hedge funds and other institutional investors.

EyePoint Pharmaceuticals Stock Down 4.8 %

EYPT stock opened at $5.81 on Friday. The stock has a 50-day simple moving average of $6.02 and a two-hundred day simple moving average of $7.52. EyePoint Pharmaceuticals, Inc. has a twelve month low of $3.91 and a twelve month high of $13.99. The firm has a market capitalization of $399.79 million, a PE ratio of -2.91 and a beta of 1.58.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.65) EPS for the quarter, meeting the consensus estimate of ($0.65). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The company had revenue of $24.50 million during the quarter, compared to analysts’ expectations of $8.84 million. On average, equities research analysts anticipate that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on EYPT shares. Chardan Capital lowered their target price on EyePoint Pharmaceuticals from $33.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday. HC Wainwright restated a “buy” rating and issued a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. Finally, StockNews.com raised shares of EyePoint Pharmaceuticals to a “sell” rating in a report on Friday, March 14th. One analyst has rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, EyePoint Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $25.29.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.